Patient and clinical characteristics (N = 53)
Men, n (%) | 30 (57) |
Median age, y (range) | 60.5 (34.7-80.9) |
Race, n (%) | |
White | 52 (98) |
Black | 1 (2) |
Symptoms and signs, n (%) | |
Fatigue | 32 (60) |
Lower extremity edema | 23 (43) |
Paresthesias | 17 (32) |
Weight loss | 17 (32) |
Dyspnea on exertion | 15 (28) |
Carpal tunnel syndrome | 14 (26) |
Enlarged tongue | 11 (21) |
Hepatomegaly | 9 (17) |
Neuropathy | 8 (15) |
Purpura | 7 (13) |
Bleeding | 3 (6) |
Pain | 2 (4) |
Status at last follow-up, n (%) | |
Dead | 41 (77) |
Alive | 11 (21) |
Lost to follow-up | 1 (2) |
Cause of death, n (%)* | |
Unknown | 24 (59) |
Cardiac failure or arrest | 10 (24) |
Infection | 3 (7) |
Myeloma | 1 (2) |
Renal failure | 1 (2) |
Cachexia | 1 (2) |
Treatment-related leukemia | 1 (2) |
Men, n (%) | 30 (57) |
Median age, y (range) | 60.5 (34.7-80.9) |
Race, n (%) | |
White | 52 (98) |
Black | 1 (2) |
Symptoms and signs, n (%) | |
Fatigue | 32 (60) |
Lower extremity edema | 23 (43) |
Paresthesias | 17 (32) |
Weight loss | 17 (32) |
Dyspnea on exertion | 15 (28) |
Carpal tunnel syndrome | 14 (26) |
Enlarged tongue | 11 (21) |
Hepatomegaly | 9 (17) |
Neuropathy | 8 (15) |
Purpura | 7 (13) |
Bleeding | 3 (6) |
Pain | 2 (4) |
Status at last follow-up, n (%) | |
Dead | 41 (77) |
Alive | 11 (21) |
Lost to follow-up | 1 (2) |
Cause of death, n (%)* | |
Unknown | 24 (59) |
Cardiac failure or arrest | 10 (24) |
Infection | 3 (7) |
Myeloma | 1 (2) |
Renal failure | 1 (2) |
Cachexia | 1 (2) |
Treatment-related leukemia | 1 (2) |
n = 41.